このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Immunocore Holdings 将来の成長

Future 基準チェック /16

Immunocore Holdings利益と収益がそれぞれ年間22.7%と17.6%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に-87.6% 21.1%なると予測されています。

主要情報

22.7%

収益成長率

21.1%

EPS成長率

Biotechs 収益成長	24.6%
収益成長率	17.6%
将来の株主資本利益率	-87.6%
アナリストカバレッジ	Good
最終更新日	06 Jun 2024

今後の成長に関する最新情報

Immunocore Holdings plc (NASDAQ:IMCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 11

Recent updates

Immunocore Holdings plc's (NASDAQ:IMCR) 28% Dip In Price Shows Sentiment Is Matching Revenues

Jun 16

Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?

May 11

Immunocore Holdings plc (NASDAQ:IMCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 11

Are Investors Undervaluing Immunocore Holdings plc (NASDAQ:IMCR) By 25%?

Apr 05

Here's Why Immunocore Holdings (NASDAQ:IMCR) Can Manage Its Debt Despite Losing Money

Jan 22

Immunocore Holdings: Vulnerable To Profit Taking After Big Rally

Jan 21

Revenues Not Telling The Story For Immunocore Holdings plc (NASDAQ:IMCR) After Shares Rise 37%

Dec 18

Some Confidence Is Lacking In Immunocore Holdings plc's (NASDAQ:IMCR) P/S

May 08

Forecast: Analysts Think Immunocore Holdings plc's (NASDAQ:IMCR) Business Prospects Have Improved Drastically

Nov 16

Immunocore: Attractive Commercial-Stage Biopharma

Oct 05

Need To Know: Analysts Are Much More Bullish On Immunocore Holdings plc (NASDAQ:IMCR)

Aug 12

Immunocore GAAP EPS of -$0.17, revenue of $38.92M

Aug 10

Immunocore to raise $140M in private placement financing

Jul 18

Analysts Are Updating Their Immunocore Holdings plc (NASDAQ:IMCR) Estimates After Its Second-Quarter Results

Aug 15

業績と収益の成長予測

NasdaqGS:IMCR - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	356	-136	-85	-13	12
12/31/2025	332	-122	-83	-75	16
12/31/2024	304	-103	-38	-29	16
3/31/2024	265	-60	-15	-12	N/A
12/31/2023	249	-55	-2	3	N/A
9/30/2023	234	-66	14	21	N/A
6/30/2023	231	-63	20	26	N/A
3/31/2023	201	-52	-6	-1	N/A
12/31/2022	174	-53	-51	-49	N/A
9/30/2022	114	-62	-55	-54	N/A
6/30/2022	82	-112	-96	-94	N/A
3/31/2022	53	-156	-134	-133	N/A
12/31/2021	36	-180	-144	-143	N/A
9/30/2021	37	-150	-137	-135	N/A
6/30/2021	39	-139	-111	-110	N/A
3/31/2021	42	-116	-83	-78	N/A
12/31/2020	41	-101	-88	-84	N/A
9/30/2020	37	-105	-91	-86	N/A
6/30/2020	34	-109	-137	-131	N/A
3/31/2020	33	-120	-146	-141	N/A
12/31/2019	34	-138	-142	-136	N/A
12/31/2018	30	-91	-26	-21	N/A
12/31/2017	19	-66	N/A	-82	N/A
12/31/2016	20	-29	N/A	-45	N/A
12/31/2015	17	20	N/A	-26	N/A
9/30/2014	10	-9	N/A	65	N/A
9/30/2013	3	-6	N/A	18	N/A

アナリストによる今後の成長予測

収入対貯蓄率: IMCR今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: IMCR今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: IMCR今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: IMCRの収益 ( 17.6% ) US市場 ( 8.5% ) よりも速いペースで成長すると予測されています。

高い収益成長: IMCRの収益 ( 17.6% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: IMCR 3 年以内に赤字になると予測されています。

Immunocore Holdings 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Consensus EPS estimates fall by 26%, revenue upgraded

Immunocore Holdings plc (NASDAQ:IMCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Consensus revenue estimates increase by 11%, EPS downgraded

Immunocore Holdings plc Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2023

Consensus EPS estimates upgraded to UK£0.80 loss, revenue downgraded

Consensus estimates of losses per share improve by 12%

Recent updates

Immunocore Holdings plc Announces Randomization of First Patient in the Global, Registrational Phase 3 Clinical Trial Testing Brenetafusp for the Treatment of First-Line Advanced or Metastatic Cutaneous Melanoma

Immunocore Holdings plc's (NASDAQ:IMCR) 28% Dip In Price Shows Sentiment Is Matching Revenues

Now 20% undervalued after recent price drop

Immunocore Holdings plc Presents KIMMTRAK Clinical Data Demonstrating That Patients with Stable Disease and Confirms Tumor Reduction Have Similar Clinical Outcomes to Patients with Partial Response

Immunocore Holdings plc Appoints Ranjeev Krishana to Serve as A Class I Director

Immunocore Holdings plc Converts Phase 2/3 TEBE-AM Clinical Trial into Registrational Phase 3 Trial Evaluating KIMMTRAK for Previously Treated Advanced Cutaneous Melanoma

Now 20% undervalued after recent price drop

Consensus EPS estimates fall by 26%, revenue upgraded

Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?

Immunocore Holdings plc (NASDAQ:IMCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

First quarter 2024 earnings released: US$0.49 loss per share (vs US$0.43 loss in 1Q 2023)

Insufficient new directors

Immunocore Holdings plc, Annual General Meeting, May 23, 2024

Are Investors Undervaluing Immunocore Holdings plc (NASDAQ:IMCR) By 25%?

Board Member notifies of intention to sell stock

Consensus revenue estimates increase by 11%, EPS downgraded

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Immunocore Holdings plc to Report Q4, 2023 Results on Feb 28, 2024

Immunocore Holdings plc Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2023

Here's Why Immunocore Holdings (NASDAQ:IMCR) Can Manage Its Debt Despite Losing Money

Immunocore Holdings: Vulnerable To Profit Taking After Big Rally

Immunocore Holdings plc Announces the Addition of Two New Pre-Clinical Candidates for Autoimmune Diseases to Its Pipeline

CEO & Director notifies of intention to sell stock

Revenues Not Telling The Story For Immunocore Holdings plc (NASDAQ:IMCR) After Shares Rise 37%

Head of Research & Development notifies of intention to sell stock

Head of Research & Development notifies of intention to sell stock

Consensus EPS estimates upgraded to UK£0.80 loss, revenue downgraded

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Head of Research & Development notifies of intention to sell stock

New major risk - Revenue and earnings growth

Head of Research & Development notifies of intention to sell stock

Head of Research & Development notifies of intention to sell stock

Consensus estimates of losses per share improve by 12%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Immunocore Holdings plc to Report Q2, 2023 Results on Aug 10, 2023

CEO & Director notifies of intention to sell stock

Head of Research & Development notifies of intention to sell stock

Consensus EPS estimates fall by 14%, revenue upgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Some Confidence Is Lacking In Immunocore Holdings plc's (NASDAQ:IMCR) P/S

No longer forecast to breakeven

Consensus EPS estimates fall by 153%, revenue upgraded

Forecast breakeven date pushed back to 2025

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus estimates of losses per share improve by 10%

Immunocore Holdings plc Provides Revenue Guidance for the Fourth Quarter and Twelve Months Ended December 31, 2022

Immunocore Holdings plc Announces the Addition of Three New ImmTAC Product Candidates

Forecast to breakeven in 2025

Consensus forecasts updated

Immunocore Holdings plc Presents Ovarian Cancer Expansion Data for ImmTAC® candidate IMC-C103C targeting MAGE-A4

An unknown buyer acquired a 5% stake in Immunocore Holdings plc (NasdaqGS:IMCR) from Malin Corporation plc (ISE:MLC) for approximately €150 million.

Consensus forecasts updated

Forecast: Analysts Think Immunocore Holdings plc's (NASDAQ:IMCR) Business Prospects Have Improved Drastically

Consensus revenue estimates increase by 27%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

High number of new directors

Immunocore: Attractive Commercial-Stage Biopharma

Consensus revenue estimates increase by 50%

Need To Know: Analysts Are Much More Bullish On Immunocore Holdings plc (NASDAQ:IMCR)

Second quarter 2022 earnings: Revenues exceed analyst expectations

Immunocore GAAP EPS of -$0.17, revenue of $38.92M

Immunocore Holdings plc to Report Q2, 2022 Results on Aug 10, 2022

High number of new directors

Immunocore Holdings plc announced that it has received $139.999988 million in funding from RTW Investments, LP, Rock Springs Capital Management LP, General Atlantic Service Company, L.P., Baker Bros. Advisors LP and another investor

Immunocore Holdings plc announced that it expects to receive $139.999988 million in funding from RTW Investments, LP, Rock Springs Capital Management LP, General Atlantic Service Company, L.P.

Immunocore to raise $140M in private placement financing

Immunocore Announces Dosing of First Patient with ImmTAV(R) Bispecific for HIV

High number of new directors

Immunocore Announces the Presentation of Initial Data from the Phase 1 Immtav® Trial for Chronic Hepatitis B At the EASL International Liver Congress™